PortfoliosLab logo
BBP vs. WDNA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

Correlation

The correlation between BBP and WDNA is 0.55, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.0
Correlation: 0.6

Performance

BBP vs. WDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Virtus LifeSci Biotech Products ETF (BBP) and WisdomTree BioRevolution Fund (WDNA). The values are adjusted to include any dividend payments, if applicable.

-60.00%-40.00%-20.00%0.00%20.00%40.00%NovemberDecember2025FebruaryMarchApril
10.90%
-46.85%
BBP
WDNA

Key characteristics

Sharpe Ratio

BBP:

0.43

WDNA:

-0.59

Sortino Ratio

BBP:

0.73

WDNA:

-0.71

Omega Ratio

BBP:

1.09

WDNA:

0.92

Calmar Ratio

BBP:

0.40

WDNA:

-0.24

Martin Ratio

BBP:

1.26

WDNA:

-1.15

Ulcer Index

BBP:

8.27%

WDNA:

12.40%

Daily Std Dev

BBP:

24.55%

WDNA:

24.27%

Max Drawdown

BBP:

-44.32%

WDNA:

-58.87%

Current Drawdown

BBP:

-16.49%

WDNA:

-52.47%

Returns By Period

In the year-to-date period, BBP achieves a -5.18% return, which is significantly higher than WDNA's -9.43% return.


BBP

YTD

-5.18%

1M

-6.64%

6M

-10.06%

1Y

8.85%

5Y*

4.50%

10Y*

6.27%

WDNA

YTD

-9.43%

1M

-3.08%

6M

-16.53%

1Y

-14.86%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


BBP vs. WDNA - Expense Ratio Comparison

BBP has a 0.79% expense ratio, which is higher than WDNA's 0.45% expense ratio.


Expense ratio chart for BBP: current value is 0.79%, compared with the broader market range of 0.00% to 2.12%.0.50%1.00%1.50%2.00%
BBP: 0.79%
Expense ratio chart for WDNA: current value is 0.45%, compared with the broader market range of 0.00% to 2.12%.0.50%1.00%1.50%2.00%
WDNA: 0.45%

Risk-Adjusted Performance

BBP vs. WDNA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BBP
The Risk-Adjusted Performance Rank of BBP is 5252
Overall Rank
The Sharpe Ratio Rank of BBP is 5353
Sharpe Ratio Rank
The Sortino Ratio Rank of BBP is 5454
Sortino Ratio Rank
The Omega Ratio Rank of BBP is 5050
Omega Ratio Rank
The Calmar Ratio Rank of BBP is 5555
Calmar Ratio Rank
The Martin Ratio Rank of BBP is 4848
Martin Ratio Rank

WDNA
The Risk-Adjusted Performance Rank of WDNA is 55
Overall Rank
The Sharpe Ratio Rank of WDNA is 44
Sharpe Ratio Rank
The Sortino Ratio Rank of WDNA is 33
Sortino Ratio Rank
The Omega Ratio Rank of WDNA is 44
Omega Ratio Rank
The Calmar Ratio Rank of WDNA is 88
Calmar Ratio Rank
The Martin Ratio Rank of WDNA is 55
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

BBP vs. WDNA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Virtus LifeSci Biotech Products ETF (BBP) and WisdomTree BioRevolution Fund (WDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for BBP, currently valued at 0.43, compared to the broader market-1.000.001.002.003.004.00
BBP: 0.43
WDNA: -0.59
The chart of Sortino ratio for BBP, currently valued at 0.73, compared to the broader market-2.000.002.004.006.008.00
BBP: 0.73
WDNA: -0.71
The chart of Omega ratio for BBP, currently valued at 1.09, compared to the broader market0.501.001.502.002.50
BBP: 1.09
WDNA: 0.92
The chart of Calmar ratio for BBP, currently valued at 0.40, compared to the broader market0.002.004.006.008.0010.0012.00
BBP: 0.40
WDNA: -0.24
The chart of Martin ratio for BBP, currently valued at 1.26, compared to the broader market0.0020.0040.0060.00
BBP: 1.26
WDNA: -1.15

The current BBP Sharpe Ratio is 0.43, which is higher than the WDNA Sharpe Ratio of -0.59. The chart below compares the historical Sharpe Ratios of BBP and WDNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.00NovemberDecember2025FebruaryMarchApril
0.43
-0.59
BBP
WDNA

Dividends

BBP vs. WDNA - Dividend Comparison

BBP has not paid dividends to shareholders, while WDNA's dividend yield for the trailing twelve months is around 0.82%.


TTM2024202320222021202020192018201720162015
BBP
Virtus LifeSci Biotech Products ETF
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.18%0.00%1.29%
WDNA
WisdomTree BioRevolution Fund
0.82%0.74%0.80%0.37%0.11%0.00%0.00%0.00%0.00%0.00%0.00%

Drawdowns

BBP vs. WDNA - Drawdown Comparison

The maximum BBP drawdown since its inception was -44.32%, smaller than the maximum WDNA drawdown of -58.87%. Use the drawdown chart below to compare losses from any high point for BBP and WDNA. For additional features, visit the drawdowns tool.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%NovemberDecember2025FebruaryMarchApril
-16.49%
-52.47%
BBP
WDNA

Volatility

BBP vs. WDNA - Volatility Comparison

Virtus LifeSci Biotech Products ETF (BBP) and WisdomTree BioRevolution Fund (WDNA) have volatilities of 14.06% and 14.02%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


4.00%6.00%8.00%10.00%12.00%14.00%NovemberDecember2025FebruaryMarchApril
14.06%
14.02%
BBP
WDNA